The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Incretin-based therapies for type 2 diabetes mellitus
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“Continuous, subcutaneous administration of native GLP-1 to patients with type 2 diabetes mellitus (T2DM) lowers fasting and postprandial levels of glucose and HbA 1c effectively, and also results in weight loss”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Three pivotal, phase III clinical trials, each of 30 weeks duration, examined the efficacy of twice-daily injections of 5 µg or 10 µg exenatide in individuals who had T2DM that was inadequately controlled with a sulfonylurea and/or metformin”
BackgroundNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Cited by
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Paul, S., & Candelario-Jalil, E. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113518 · Cited by 748
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Fluorogenic probes for disease-relevant enzymes
Zhang, J., Chai, X., He, X.-P., Kim, H.-J., Yoon, J., & Tian, H. (2019) · Chemical Society Reviews · doi:10.1039/c7cs00907k · Cited by 606
Gut microbiota, obesity and diabetes
Patterson, E., Ryan, P. M., Cryan, J. F., Dinan, T. G., Ross, R. P., Fitzgerald, G. F., & Stanton, C. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133285 · Cited by 552
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515
“The magnitude of sucrose intake supEndocrinology, February 2012, 153(2):647–658 endo.”
BackgroundInfluentialPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Shah, Z., Kampfrath, T., Deiuliis, J. A., Zhong, J., Pineda, C., Ying, Z., Xu, X., Lu, B., Moffatt-Bruce, S., Durairaj, R., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.041418 · Cited by 377
Hydrogel drug delivery system with predictable and tunable drug release and degradation rates
Ashley, G. W., Henise, J., Reid, R., & Santi, D. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215498110 · Cited by 376
Peptides Containing β-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry
Cabrele, C., Martinek, T. A., Reiser, O., & Berlicki, Ł. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010896 · Cited by 368
Tsuda, T. (2018) · Food & Function · doi:10.1039/c7fo01242j · Cited by 367
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1314 · Cited by 321
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Self-citationInsulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment
Li, X., Leng, S., & Song, D. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s74042 · Cited by 292
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Sauvé, M., Ban, K., Momen, M. A., Zhou, Y.-Q., Henkelman, R. M., Husain, M., & Drucker, D. J. (2010) · Diabetes · doi:10.2337/db09-0955 · Cited by 264
Self-citationSalcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 259
Transgenic pigs as models for translational biomedical research
Aigner, B., Renner, S., Kessler, B., Klymiuk, N., Kurome, M., Wünsch, A., & Wolf, E. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0610-9 · Cited by 258
Williams-Herman, D., Engel, S. S., Round, E., Johnson, J., Golm, G. T., Guo, H., Musser, B. J., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-7 · Cited by 258
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
Drucker, D. J., Dritselis, A., & Kirkpatrick, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3148 · Cited by 181
Self-citationBrain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Chow, H.-M., Shi, M., Cheng, A., Gao, Y., Chen, G., Song, X., So, R. W. L., Zhang, J., & Herrup, K. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0505-1 · Cited by 171
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166
“GLP-1R agonists and dipeptidyl peptidase-4 inhibitors are approved for the treatment of type 2 diabetes [22] and are being examined in clinical trials of islet transplantation in patients with type 1 diabetes [16, 17], an autoimmune disorder resulting from defective immunoregulation [23, 24].”
BackgroundSelf-citationUmpierrez, G. E., Gianchandani, R., Smiley, D., Jacobs, S., Wesorick, D. H., Newton, C., Farrokhi, F., Peng, L., Reyes, D., Lathkar-Pradhan, S., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0277 · Cited by 166
Benninger, R. K. P., Head, W. S., Zhang, M., Satin, L. S., & Piston, D. W. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.218909 · Cited by 165
Xiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.246207 · Cited by 164
Horton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156
Schmidt, H. D., Mietlicki-Baase, E. G., Ige, K. Y., Maurer, J. J., Reiner, D. J., Zimmer, D. J., Van Nest, D. S., Guercio, L. A., Wimmer, M. E., Olivos, D. R., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.362 · Cited by 148
Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149
“Glucagon-like peptide-1 (GLP-1),(2) an incretin hormone, produced by post-translational processing of proglucagon gene (14, 15) in enteroendocrine L-cells in response to food intake, is secreted as one of the gut hormones (15, 16) and collected in the intestinal lymph duct.”
BackgroundGusarova, V., O’Dushlaine, C., Teslovich, T. M., Benotti, P. N., Mirshahi, T., Gottesman, O., Van Hout, C. V., Murray, M. F., Mahajan, A., Nielsen, J. B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04611-z · Cited by 145
Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control
Lang Lehrskov, L., Lyngbaek, M. P., Soederlund, L., Legaard, G. E., Ehses, J. A., Heywood, S. E., Wewer Albrechtsen, N. J., Holst, J. J., Karstoft, K., Pedersen, B. K., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.008 · Cited by 135
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125
The role of gut hormone peptide YY in energy and glucose homeostasis: Twelve years on
Manning, S., & Batterham, R. L. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170404 · Cited by 124
Minireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
Brubaker, P. L. (2010) · Endocrinology · doi:10.1210/en.2010-0115 · Cited by 122
Hayes, M. R., Kanoski, S. E., Alhadeff, A. L., & Grill, H. J. (2011) · Obesity · doi:10.1038/oby.2011.50 · Cited by 110
Yang, X., Feng, P., Zhang, X., Li, D., Wang, R., Ji, C., Li, G., & Hölscher, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107748 · Cited by 103
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102
Dual Role of VAMP8 in Regulating Insulin Exocytosis and Islet β Cell Growth
Zhu, D., Zhang, Y., Lam, P. P. L., Dolai, S., Liu, Y., Cai, E. P., Choi, D., Schroer, S. A., Kang, Y., Allister, E. M., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.001 · Cited by 87
Hayes, M. R., Kanoski, S. E., De Jonghe, B. C., Leichner, T. M., Alhadeff, A. L., Fortin, S. M., Arnold, M., Langhans, W., & Grill, H. J. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00356.2011 · Cited by 86
Wu, B., Wei, S., Petersen, N., Ali, Y., Wang, X., Bacaj, T., Rorsman, P., Hong, W., Südhof, T. C., & Han, W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513004112 · Cited by 76
The Role of GLP-1 in Neuronal Activity and Neurodegeneration
Hölscher, C. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00013-8 · Cited by 74
Osteocalcin effect on human β-cells mass and function
Sabek, O. M., Nishimoto, S. K., Fraga, D., Tejpal, N., Ricordi, C., & Gaber, A. O. (2015) · Endocrinology · doi:10.1210/en.2015-1143 · Cited by 74
Salles, G. N., Calió, M. L., Hölscher, C., Pacheco-Soares, C., Porcionatto, M., & Lobo, A. O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107813 · Cited by 71
Basalay, M. V., Davidson, S. M., & Yellon, D. M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06915-8 · Cited by 68
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
D'Alessio, D., Häring, H. ‐., Charbonnel, B., de Pablos‐Velasco, P., Candelas, C., Dain, M. ‐., Vincent, M., Pilorget, V., Yki‐Järvinen, H., & on behalf of the EAGLE Investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12406 · Cited by 56
“This effect has also been shown with the GLP-1 receptor agonists exenatide and lixisenatide, which delay gastric emptying as well as regulate islet hormone release, responses that are effective in maintaining glycaemia after eating [11,22,23].”
BackgroundResultZhou, T., Zhang, M., Zhao, L., Li, A., & Qin, X. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00093.2016 · Cited by 54
Synaptotagmin-7 Functions to Replenish Insulin Granules for Exocytosis in Human Islet β-Cells
Dolai, S., Xie, L., Zhu, D., Liang, T., Qin, T., Xie, H., Kang, Y., Chapman, E. R., & Gaisano, H. Y. (2016) · Diabetes · doi:10.2337/db15-1436 · Cited by 55
Douton, J. E., Horvath, N., Mills‐Huffnagle, S., Nyland, J. E., Hajnal, A., & Grigson, P. S. (2022) · Addiction Biology · doi:10.1111/adb.13117 · Cited by 54
“Both peripheral and central GLP-1 are involved in regulating blood glucose levels and food intake, and GLP-1 receptor ligand pharmacotherapies are used as current treatments for obesity and type 2 diabetes in humans.(12,13) Additionally, it has been observed that GLP-1 analogues not only produce satiety(14) but also r…”
BackgroundBlockade of Na+ Channels in Pancreatic α-Cells Has Antidiabetic Effects
Dhalla, A. K., Yang, M., Ning, Y., Kahlig, K. M., Krause, M., Rajamani, S., & Belardinelli, L. (2014) · Diabetes · doi:10.2337/db13-1562 · Cited by 53
“The effect was similar to that reported with GLP-1 receptor agonists, which also inhibit glucagon secretion, albeit via a different mechanism (27).”
Martin, C. M. A., Irwin, N., Flatt, P. R., & Gault, V. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.03.011 · Cited by 53
Diabetes Care After Transplant
Wallia, A., Illuri, V., & Molitch, M. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.01.005 · Cited by 50
He, L., Zhang, S., Zhang, X., Liu, R., Guan, H., & Zhang, H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s150701 · Cited by 40
Direct cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
“going trials [26].”
Dorecka, M., Siemianowicz, K., Francuz, T., Garczorz, W., Chyra, A., Klych, A., & Romaniuk, W. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71069-7 · Cited by 36
“sociated body weight loss [6, 21].”
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
Curcumin induces secretion of glucagon-like peptide-1 through an oxidation-dependent mechanism
Alli-Oluwafuyi, A.-M., Luis, P. B., Nakashima, F., Giménez-Bastida, J. A., Presley, S. H., Duvernay, M. T., Iwalewa, E. O., & Schneider, C. (2019) · Biochimie · doi:10.1016/j.biochi.2019.08.013 · Cited by 28
“GLP-1 targeting drugs act as GLP-1 receptor agonists or inhibitors of the GLP-1 degrading enzyme, dipeptidylpeptidase IV (11).”
BackgroundLee, J., Hong, S.-W., Kim, M.-J., Moon, S. J., Kwon, H., Park, S. E., Rhee, E.-J., & Lee, W.-Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1293 · Cited by 20
Metadata
- Authors
- Lovshin, J. A., & Drucker, D. J.
- Venue
- Nature Reviews Endocrinology
- Published
- 2009-05
- Volume
- 5
- Issue
- 5
- Pages
- 262-269
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W1967256054
- Cited by
- 649
- References
- 52
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.